Trial Profile
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Pemetrexed (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- Acronyms PrE0505
- 29 Jun 2023 Status changed from active, no longer recruiting to completed.
- 14 Sep 2021 Results of whole exome sequencing analysis assessing genomic and immune cell response to chemo-immunotherapy in malignant pleural mesothelioma patients presented at the 2021 World Conference on Lung Cancer
- 11 Mar 2021 Time frame of primary endpoint changed from 72 to 32 months.